Research output per year
Research output per year
Personal profile
Research interests
Onderzoeksbelangen
Fingerprint
Dive into the research topics where Michel Zwaan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel
Zwaan, C. M., Tasian, S. K., Aplenc, R., Brodersen, L. E., Buldini, B., De Moerloose, B., Dworzak, M. N., Fogelstrand, L., Gibson, B. E. S., Goemans, B. F., Hasle, H., Hirsch, B. A., Kaspers, G. J. L., Klusmann, J. H., Kutny, M. A., Lehrnbecher, T., Locatelli, F., Meshinchi, S., Petit, A. & Pigazzi, M. & 5 others, , 2 Apr 2026, In: Blood. 147, 14, p. 1532-1561 30 p.Research output: Contribution to journal › Comment/debate
14 Citations (Scopus) -
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial
Gray, J. C., Weston, R., Owens, C., Canete, A., Gambart, M., De Wilde, B., Nysom, K., van Eijkelenburg, N., Ladenstein, R., Castellano, A., Gerber, N. U., Marshall, L. V., Barone, G., Rubio-San-Simon, A., Ng, A., Vaidya, S., Gallego, S., Makin, G., Burke, G. A. A. & McCarthy, A. & 27 others, , 20 Jan 2026, In: Journal of Clinical Oncology. 44, 3, p. 176-187 12 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Citations (Scopus) -
Eligibility criteria in pediatric oncology phase I and II clinical trials: Analysis and recommendations for standardization from the Innovative Therapies for Children and Adolescents with Cancer (ITCC) Consortium
on behalf of the Innovative Therapies For Children and Adolescents With Cancer Consortium (ITCC)., 25 Jun 2026, In: European Journal of Cancer. 242, 116830.Research output: Contribution to journal › Article › peer-review
-
Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial
Peccatori, N., Locatelli, F., Ammerlaan, A. C. J., Jiang, Y., van der Velden, V. H. J., Lissat, A., Nilsson, A., Bielorai, B., Moerloose, B. D., Rives, S., Rubio-San-Simon, A., Dirksen, U., Engstler, G., Bruno, B., Diaz-de-Heredia, C., Brethon, B., Sirvent, F. B., Rialland, F., Sramkova, L. & Pasquet, M. & 10 others, , Jul 2026, In: The Lancet Haematology. 13, 7, p. e449-e459Research output: Contribution to journal › Article › peer-review
-
Multi-tyrosine kinase inhibitors in paediatric soft tissue sarcoma – A review
Schellekens, K. P. J., Ferrari, A., Meister, M. T., Zwaan, C. M., Gatz, S. A., van Noesel, M. M., Casanova, M. & Schoot, R. A., Jun 2026, In: EJC Paediatric Oncology. 7, 100484.Research output: Contribution to journal › Review article › peer-review
Open Access